Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-037768
Filing Date
2020-08-06
Accepted
2020-08-06 16:18:24
Documents
57
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q achv-10q_20200630.htm 10-Q 1950814
2 EX-31.1 achv-ex311_6.htm EX-31.1 9044
3 EX-31.2 achv-ex312_7.htm EX-31.2 9080
4 EX-32.1 achv-ex321_8.htm EX-32.1 4826
5 EX-32.2 achv-ex322_9.htm EX-32.2 4851
  Complete submission text file 0001564590-20-037768.txt   6824528

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT achv-20200630.xml EX-101.INS 1294088
7 XBRL TAXONOMY EXTENSION SCHEMA achv-20200630.xsd EX-101.SCH 57478
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE achv-20200630_cal.xml EX-101.CAL 42493
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20200630_def.xml EX-101.DEF 248076
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20200630_lab.xml EX-101.LAB 433217
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20200630_pre.xml EX-101.PRE 348001
Mailing Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101
Business Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 201081932
SIC: 2835 In Vitro & In Vivo Diagnostic Substances